Novaquest Capital Management
VC Fund
Raleigh, United States
Novaquest Capital Management is a VC fund in Raleigh focused on Biotechnology and Health Care. NovaQuest Capital Management, LLC (NovaQuest) manages product and company investments in the global healthcare industry. Its primary focus is structured finance investments in late-stage clinical and commercialized biopharmaceutical products. NovaQuest invests side-by-side with global companies in their most strategic product programs, ensuringalignment with the biopharmaceutical companies. These customized, product transactions are an alternative to standard biopharmaceutical industry deal-making and help companies maximize the value of their product portfolios. In addition, NovaQuest invests in select private equity and other company securities, with a consistent focus on late-stage clinical and commercialized products.The NovaQuest team has worked together for over 12 years, investing over $1 billion into the global healthcare industry. The team began pursuing its strategy in 2000 as an investment group within Quintiles Transnational Holdings Inc. (Quintiles). Today, NovaQuest Capital Management is an independent firm managing global investment capital. It is backed by investors whose relationships with NovaQuest date back to the group’s inception. NovaQuest is meeting the evolving needs of global healthcare companies and its investors with a consistent strategy, developed over multiple years and transactions, that draws on a customized mix of investment and return elements and securities.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 47%
- Fund size:
- $275M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Novaquest Capital Management invests in
Stages Novaquest Capital Management invests in
Countries Novaquest Capital Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.6M–$210M
- Private Equity
- $5.3M–$200M
- Post-IPO Equity
- $50M–$125M
Investment Focus
Industry
- Biotechnology 21 (66%)
- Health Care 12 (38%)
- Pharmaceutical 10 (31%)
- Therapeutics 7 (22%)
- Medical 5 (16%)
Stage
- Private Equity 7 (22%)
- Series A 5 (16%)
- Post-IPO Equity 3 (9%)
- Series C 2 (6%)
- Series D 2 (6%)
Country
- United States 17 (53%)
- New Zealand 2 (6%)
- United Kingdom 2 (6%)
- Israel 1 (3%)
- Sweden 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Brian Axe
Partner
|
Partner | Total investments: 6 | Find email | |
Dennis Gillings
Executive Chairman
|
Executive Chairman | Total investments: 0 | Find email | |
Derek Winstanly
Chief Customer & Governance Officer
|
Chief Customer & Governance Officer | Total investments: 0 | Find email | |
James Erlinger
General Counsel
|
General Counsel | Total investments: 0 | Find email | |
Paula Brown Stafford
president
|
president | Total investments: 0 | Find email | |
| See all 16 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mirna
|
Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology. | $3.6M / Series A / Dec 10, 2025 | |
Gallant
|
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order toelevate the quality of life for all pets and the people that love them. | $18M / Series B / Mar 15, 2025 | |
|
Mirna
|
Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology. | $4.1M / Series A / Jul 02, 2024 | |
Kyntra Bio
|
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissuegrowth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration). | $50M / Post-IPO Debt / Nov 07, 2022 | |
Phathom Pharmaceuticals
|
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acidblocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies. | $40M / Post-IPO Debt / Nov 01, 2022 | |
Hansa Biopharma
|
Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic ordisease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications. | $70M / Grant / Jul 18, 2022 | |
TARGAN
|
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effectivevaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick. | $35M / Series C / May 25, 2022 | |
Dermavant Sciences
|
Dermavant Sciences is a biotechnology company focused on dermatology. | $160M / Private Equity / Jun 07, 2021 | |
Argenta
|
Argenta is a contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. | $30M / Private Equity / May 20, 2021 | |
|
Argenta
|
Argenta is a contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. | $30M / Private Equity / May 20, 2021 | |
| See all 32 investments → | |||
Co-Investors
Essex Woodlands Healthcare Partners
3 deals together
NovaQuest
3 deals together
Animal Health Angels
2 deals together
BPV Capital Management
2 deals together
EDBI
2 deals together
Andera Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Novaquest Capital Management invest in?
Novaquest Capital Management invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Private Equity and Series A stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Novaquest Capital Management's check size?
Novaquest Capital Management typically joins rounds of $3.6M–$210M at Series A, $5.3M–$200M at Private Equity and $50M–$125M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Novaquest Capital Management participates in.
How do I contact Novaquest Capital Management?
Public channels for Novaquest Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novaquest Capital Management?
The team at Novaquest Capital Management includes Brian Axe (Partner), Dennis Gillings (Executive Chairman) and Derek Winstanly (Chief Customer & Governance Officer), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
